Clinical Trials · NCT00632242
ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Archemix Corp.
- Enrollment
- 28
- Start date
- Jan 2008
- Locations
- 1 site, Austria
- Primary endpoint
- To establish the overall safety and tolerability of ARC1779 in three varieties of von Willebrand Factor (vWF)-related platelet function disorders